# Lassen Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lassen-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.lassentherapeutics.com/
- Total disclosed funding: $116M
- Latest round: Series B (Dec 19, 2023)
- Investors on record: 7

## About

Founded in 2019 and based in California, US, Lassen Therapeutics, LLC operates as a health technology company that develops and manufactures novel medicines for rare diseases. As of 2023, the firm is headed by its CEO Maria Fardis. In December 2023, the firm raised USD 85 million in Series B funding co-led by returning investor Frazier Life Sciences and investor Longitude Capital, with participation from investors BVF Partners and Catalio Capital Management. Returning investors Alta Partners and Longwood Fund also participated in this round.

The company develops antibodies as potential treatments for fibrosis, rare diseases, oncology, and thyroid eye disease. The firm science includes IL-11 which serves as the treatment for fibro-inflammatory diseases such as thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF). 

The company plans to use the December 2023 funding to support LASN01 clinical program and advance IND-enabling activities for LASN500.

## Funding rounds

- Series B, Dec 19, 2023, $85M — Alta Partners, Longitude Capital, Longwood Fund, BVF Partners, Catalio Capital Management, Frazier Life Sciences Management, Lp
- Series A, Jun 17, 2020, $31M — Alta Partners, Frazier Healthcare Partners, Longwood Fund

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A, Series B
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series A, Series B
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series B
- Frazier Life Sciences Management, Lp — Series B